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Introduction
Prostate cancer patients reportedly show increased levels of cancer fear and mood disturbances compared to other cancer patients. However, information regarding the effects of stress hormones on prostate cancer cells, and on responses of prostate tumors to therapies, is limited. We hypothesize that epinephrine released after emotional stress activates anti-apoptotic signaling pathways in prostate tumors, and contributes to the resistance of advanced prostate cancer to therapies. To test this hypothesis, we propose to examine if stress/epinephrine induces the activation of PKA and BAD phosphorylation in prostate tumors; and determine if stress/epinephrine reduces therapeutic efficacy of anti-cancer treatments.
During the first year (June 2008-May 2009) we proposed to conduct following experiments: Months 1-12
Test if stress/epinephrine activates PKA and increases BAD phosphorylation in subcutaneous xenografts.
Months 6-18
Test if stress/epinephrine activates PKA and increases BAD phosphorylation in xenografts implanted in bones.
Body

Stress/Epinephrine-induced PKA activation and Bad phosphorylation in subcutaneously implanted prostate cancer xenografts.
In recent publication we have shown that epinephrine protects prostate cancer cells from apoptosis by activating PKA that in turn phosphorylates BAD (1) . The task 1 of SOW was to determine whether subjecting mice to emotional stress will induce PKA activation and BAD phosphorylation in prostate cancer xenografts and also to test whether effects of stress are mediated via beta 2 adrenoreceptors (β2-AR). To determine whether effects of stress on PKA activation BAD phosphorylation and apoptosis are mediated via epinephrine/beta2-AR we planned to use antagonists of β2-AR: propranolol and ICI118,551. Experiments were planned as follows: 1) test whether β2-AR antagonists (propranolol or ICI118,551) will block anti-apoptotic effect of epinephrine and BAD phosphorylation induced by epinephrine in C42Luc cells (this is positive control for in vivo experiments with C42Luc xenografts) 2) examine status of CREB phosphorylation in C42Luc xenografts 3) examine status of BAD phosphorylation in C42Luc xenografts 4) test whether inhibitors of PI3K will lead to AKT and BAD dephosphorylation in C42Luc xenografts 5) test whether stress or epinephrine injection will restore BAD phosphorylation in C42Luc xenografts treated with PI3K inhibitors.
1) Test whether β2-AR antagonists (propranolol or ICI118,551) will block anti-apoptotic effect of epinephrine and BAD phosphorylation induced by epinephrine in C42Luc cells (positive control for in vivo experiments with C42Luc xenografts).
Experiments with β2-AR selective antagonist ICI118,551 have shown that it inhibits anti-apoptotic effects of epinephrine but not of vasoactive intestinal peptide that acts via VPAC1 receptors nor the antiapoptotic effect of forskolin, a direct activator of adenylyl cyclase (Fig.1 A) . Consistently, pre-treatment with propranolol prevented epinephrine-induced phosphorylation of both CREB and BAD (Fig.1B lanes 4, 6, 9) . These experiments also showed that in C42 cells that grow in either serum free media or in the presence of serum, BAD is constitutively phosphorylated and only minor increase over background phosphorylation could be detected after epinephrine treatment (compare lane 1 with lanes 3 and 5). Pre--3-treatment with PI3K inhibitor LY294002 completely abolished BAD phosphorylation at S112; while epinephrine added 1h after LY294002 restored BAD phosphorylation. Epinephrine-induced BAD phosphorylation was blocked in the presence of 10µM of propranolol ( Fig.1B lanes 7,8,9 ).
These results led us to following conclusions: a) Propranolol could be used to inhibit activation of β2-AR/PKA/BAD pathway in C42 cells by epinephrine. If propranolol will inhibit stress-induced activation of PKA and BAD phosphorylation in C42 xenografts in vivo it will confirm that effect of stress are mediated via β2-AR. b) Effects of stress/epinephrine on BAD phosphorylation in C42 xenografts should be studied in the presence of PI3K inhibitors that eliminate constitutive BAD phosphorylation. c) Phosphorylation of ectopically expressed HA-BAD mirrors endogenous BAD phosphorylation, thus analysis of HA-BAD allows adequately interpret modifications of endogenous BAD. d) Other GPCR agonists may potentially activate PKA/BAD pathway and protect prostate cancer cells from apoptosis.
2) Examine status of CREB phosphorylation in C42Luc xenografts
Our pilot data have shown that in C42Luc xenografts CREB is not phosphorylated unless mice are subjected to emotional stress (Fig.2 A) .
However, more extensive analysis of CREB phosphorylation in C42Luc xenografts showed that in some cases CREB was phosphorylated in tumors of mice that were not subjected to stress (not shown). Furthermore we observed substantial variations in CREB phosphorylation in mice subjected to stress with or without prior injection of propranolol (Fig. 2B ). This is a striking discord with our tissue culture data, that consistently show CREB phosphorylation when cell are treated with agonists that activate PKA, and lack of epinephrine-induced CREB phosphorylation in cells pretreated with propranolol (Fig.  1B) .
Subsequent measurements of epinephrine in blood collected from mice showed that response to stress is significantly varied between individual mice. Even gentle handling triggers epinephrine spike in some mice while others may not respond to stressful treatments. Since propranolol will prevent activation of β2-AR/PKA pathway only if injected prior to stress, CREB could be phosphorylated even in mice injected with propranolol. To reduce stress from handling we plan to handle mice daily for at least a week prior to follow-up experiments. We also perfected in-house epinephrine measurements in mouse blood by ELISA. Pilot experiments have shown that continuous handling throughout the week combined with isoflurane anesthesia prior to intratumoral injections permits keeping epinephrine levels below 1nM in Fig. 1 . Antagonists of β2-AR inhibit epinephrine-induced survival and phosphorylation of CREB and BAD. a) Cells were put in serum free media and treated with apoptosis-inducing agents (combination of LY294002 and thapsigargin) alone or in combination with ICI118,551 (ICI, 10µM) where indicated, followed by epinephrine (Epi, 100nm), Vasoactive intestinal peptide (VIP, 100nM), Forskolin (Fsk, 5µM). Three hours later cells were collected and caspase activity measured with fluorescent substrate DEVD-afc. b) Cells were pretreated with 10µM of propranolol alone or in combination with LY294002, followed by epinephrine. One hour later cells were lysed and phosphorylation of CREB and BAD was examined by Western blotting.
-4-60% mice. These data indicate that assignment of tumor samples for analysis of signaling pathways should be done based on blood epinephrine measurements.
Given the individual variability in stress response, the lack of tools that allow continuous monitoring activation of PKA pathway in xenograft tumors poses a formidable problem. To create such tool we decided to generate C42 cells that express luciferase under control of CRE response element. In order to increase CRE-driven expression of luciferase to the level that permit detecting luminescence in xenografts in vivo we used GAL-VP16 two-step transcriptional amplification system (2) . Generation of cell lines that stably express CRE-driven luciferase is currently under way. We anticipate that noninvasive monitoring of CRE reporter combined with biochemical analysis of CREB phosphorylation will permit a comprehensive analysis of stress-induced activation of PKA pathway in C42 xenografts in vivo.
1.3) Examine status of BAD phosphorylation in C42Luc xenografts.
Analysis of BAD phosphorylation in C42Luc xenografts showed that BAD is constitutively phosphorylated in xenografts in vivo (Fig. 3A) 1. 4) Test whether inhibitors of PI3K will lead to AKT and BAD dephosphorylation in C42Luc xenografts.
In contrast to results obtained with C42 cells in tissue culture that show parallel reduction of phosphorylation of both Akt and BAD (3, 4) , after injections of LY294002 into xenograft tumors BAD remained phosphorylated despite Akt phosphorylation was substantially reduced (Fig. 3A) Analysis of the dynamics of Akt phosphorylation in xenografts tumors has shown that Akt remains dephosphorylated for only 40 min, unlike in tissue culture, where Akt remains dephosphorylated for several hours. Based on tissue culture experiments BAD is expected to be de-phosphorylated within 2 hours after Akt de-phosphorylation (Sastry et al, JBC 281, pp. 20891-20901supplem. figure 1) To maintain PI3K/Akt pathway continuously inhibited for several hours we repeatedly injected LY294002 into C42LucBAD xenografts. Still, BAD remained phosphorylated even 3h after LY294002 injections began. This result suggests that BAD de-phosphorylation in vivo could take longer than in tissue culture. To maintain PI3K/Akt pathway inhibited for longer period of time we plan to substitute LY294002 with another PI3K inhibitor ZSTK474. Pilot experiments have shown that ZSTK474 inhibits PI3K and induces apoptosis at 0.5µM which is 40 fold lower concentration than LY29002 (Fig. 3B) . In vivo testing of ZSTK474 is currently ongoing. 
5) Test whether stress or epinephrine injection will restore BAD phosphorylation in C42Luc xenografts treated with PI3K inhibitors.
Until we are successful in de-phosphorylating BAD in C42 xenografts we will not be able to reliably test whether stress/epinephrine signaling restores BAD phosphorylation in vivo.
Test if stress/epinephrine activates PKA and increases BAD phosphorylation in xenografts implanted in bones.
C42Luc tumors that grow in bones are mixed with mouse tissues (Fig. 4 ) Therefore the best way of selectively following BAD and CREB phosphorylation in tumors as oppose to stroma is by generating C42Luc cells that express BAD or CREB. We already generated C42LucBAD cells that express HA-BAD. HA-BAD could be selectively immunoprecipitated from tumors and phosphorylation at S112, S136 and S155 could be followed by Western blotting with phospho-specific antibodies (Fig. 3A ). However unlike with subcutaneous xenografts it may not be feasible to directly inject PI3K inhibitors into xenografts implanted in bones. Therefore prior to experiments with xenografts implanted into bones we need to demonstrate that systemic injections of PI3K inhibitor de-phosphorylate Akt and BAD. For these experiments will use ZSTK474 that will be injected intraperitoneally into mice with subcutaneously implanted C42 xenografts. As positive control ZSTK474 will be injected directly into subcutaneous C42 xenografts. After effects of systemic injection of ZSTK474 on Akt and BAD de-phosphorylation will be demonstrated in mice with subcutaneous xenografts experiments will be continued with C42cells implanted in bones.
As alternative approach to pharmacological inhibition of PI3K we resort to inducible expression of PTEN lipid phosphatase in C42 cells. C42 cells do not express PTEN due to frame-shift mutation. Earlier publication has shown that re-expression of PTEN turns off -6-constitutive PI3K pathway in LNCaP cells (2) . Since C42 cells were derived from LNCaP we anticipate that inducible expression of PTEN will lead to dephosphorylation of both Akt and BAD in C42 cells as well.
1. We have shown that in tissue culture antagonists of β2-AR inhibit epinephrine-induced activation of PKA and BAD phosphorylation as well as anti-apoptotic effect of epinephrine. This information opens doors to test the role of epinephrine/β2-AR in activation of PKA/BAD pathway in vivo.
Key Research Accomplishments
2. We showed that intratumoral injections of LY294002 cause only transient (40 min) inhibition of PI3K/Akt pathway in C42 xenografts. Thus, repeated injections are required to achieve continuous inhibition of PI3K pathway.
3. We have shown that CREB phosphorylation correlates with increased blood epinephrine levels. Thus, it is necessary to measure blood epinephrine levels in order to confirm that mice either calm or stressed.
1. We generated C42Luc cells that inducibly express PKA inhibitor PKI-GFP.
Reportable Outcomes
2. We have submitted a manuscript that describes the role of BAD in prostate xenograft growth (see appendix).
3. We generated CRE-TSTA construct that could be used to monitor induction of CRE in tumors in vivo by non-invasive imaging.
We have reagents at hand to test the role of β2-AR in stress-induced activation of PKA. PKA activity could be judged by phosphorylation of CREB and BAD. Although BAD phosphorylation is more relevant to anti-apoptotic effect of epinephrine, CREB could be used as biomarker of PKA activation. Still, additional experiments are needed to reliably monitor activation of PKA and BAD phosphorylation in vivo. Thus, in order to establish a connection between stress and PKA activation in tumors we need to condition mice so they will not be stressed by handling. We already know that repetitive handling is reducing stress response (based on measurements of blood epinephrine levels) and experiments are under way to establish the correlation between epinephrine levels and CREB phosphorylation.
Conclusion
As alternative approach we developing tools to monitor PKA activity by noninvasive optical imaging.
Since C42 cells are PTEN deficient, PI3K/Akt pathway is constitutively active and BAD is constitutively phosphorylated in these cells. Thus, to determine whether BAD could be phosphorylated by stress/epinephrine in vivo we need to inhibit PI3K in C42 xenografts. To accomplish this two approaches are under way: first, to use new PI3K inhibitor ZSTK474, second to generate cells that inducibly express PTEN phosphatase. androgen-independent advanced prostate cancer [2] . Mechanisms that enable prostate cancer cells to evade apoptosis may contribute to therapeutic resistance. Thus, increased levels of several growth factors, including FGF, EGF, IL-6 and GPCR agonists that activate anti-apoptotic signaling pathways, have been reported in androgen-independent prostate cancer [3] [4] [5] [6] [7] . Anti-apoptotic signals could either post-translationally modify apoptosis regulatory proteins or change their expression levels. Indeed, increased expression of anti-apoptotic Bcl-2 proteins as well as inhibitors of apoptosis proteins (IAPs) in advanced prostate cancer has been reported [8, 9] . Also, we have recently shown that in prostate cancer cells, the pro-apoptotic Bcl-2 protein BAD plays a unique role as a convergence point of several anti-apoptotic signaling pathways that include constitutively active PI3K, activated EGFR and GPCR [6] .
BAD, bcl-xl/bcl-2-antagonist causing cell death, was initially identified in a yeast two hybrid screen interacting with Bcl-2 or Bcl-xl [10] . BAD is a unique BH3-only family member in that its regulation is primarily mediated through its conserved phosphorylation sites (serines 112, 136, and 155 based on the mouse sequence) [11, 12] . Phosphorylated BAD fails to bind Bcl-XL or Bcl-2 proteins, and has been considered an apoptosis sentinel inactivated by anti-apoptotic signals.
Upon withdrawal of survival factors BAD becomes dephosphorylated, shifts the balance of pro-and anti-apoptotic Bcl proteins that triggers release of cytochrome c, SMAC and AIF from mitochondria and subsequently leads to apoptosis [12] . Thereby, it would not be surprising if cancer cells attempted to decrease BAD expression. A recent study has shown that BAD expression is elevated in prostatic carcinomas compared to low expression in normal prostatic epithelium [13] . It seems counterintuitive that prostate cells would dedicate extra resources to maintain BAD phosphorylation instead of eliminating its expression. It is possible that in addition to regulating apoptosis, BAD might play a positive role in prostatic tumor growth.
In this study, we found that increased BAD expression stimulates proliferation of prostate 
Materials and Methods
Cell lines -Prostate cancer cell lines, LNCaP and C4-2, were gifts from Dr. Leland Chung (Emory University, Atlanta GA). C4-2BADLuc cells were generated by transfecting C4-2 cells with wildtype BAD (HA-BAD-pTRE2hygro) and firefly luciferase (PGL3) whereas pTRE2hygro and firefly luciferase (PGL3) were transfected into C4-2 cells to generate C4-2Luc. LNCaP cells were maintained with T-medium supplemented with 5% fetal bovine serum, and C4-2 cells were maintained with RPMI 1640 with 10% fetal bovine serum. All cells were kept at 5% CO 2 at 37° C. Statistical analysis -To determine whether differences between data sets were statistically significant, Student's t-test analysis (two-tailed distribution; two-sample unequal variance) was performed using Excel software.
Antibodies and Other Reagents -Antibodies
-7- (Fig. 1A, B) . To exclude the possibility that increased proliferation of cells that stably express BAD was due to clonal variations, we compared proliferation in cells transiently transfected with either BAD or empty vector. These experiments showed increased proliferation in several cell lines that transiently express BAD (Fig 1C) .
Since C4-2 cells are derived from metastatic prostate cancer [15] , it is possible that they may have already established optimal levels of BAD. Therefore, we examined the effect of knocking down BAD expression on proliferation of these cells. C4-2Luc cells were infected with lentiviral vectors that encode scrambled shRNA or BAD shRNA. Reduced expression of BAD led to decreased proliferation of C4-2 cells (Fig. 1 D, E) . Measuring luminescence instead of physical tumor size permits detection of xenograft growth prior to the appearance of palpable subcutaneous tumors. This approach reduces the time required to measure kinetics of tumor growth. Analysis of luminescence of C4-2Luc and C4-2LucBAD xenografts showed increased tumor take and faster tumor growth of C4-2LucBAD xenografts (Fig.   2AB ). Consistent with results of luminescence analysis, C4-2LucBAD cells produced palpable tumors at higher frequency comparing to C4-2Luc cells (Fig. 2C ). In accordance with the faster growth of C4-2LucBAD xenografts, immunohistochemical analysis showed an increased number of cells that stained positive for the proliferative marker Ki-67 compared to C4-2Luc xenografts (Fig.   2D ). Parallel to experiments with C4-2LucBAD cells, experiments were conducted with C4-2Luc cells in which endogenous BAD expression was inhibited by the shRNA approach. C4-2Luc cells were infected with the lentiviral vector pLL3.7 that expressed BAD shRNA or scrambled shRNA, and the cells were then implanted subcutaneously into nude mice. Luminescence of C4-2Luc xenografts was followed for one week as shown in Fig. 3 . C4-2Luc xenografts with a reduced expression of BAD showed reduced tumor take and grew at a slower rate than cells with intact BAD expression.
-9- have suggested that BAD protein can be involved in promoting cell cycle progression [16, 17] .
Thus, fibroblasts with increased expression of Bcl-2/BclXL are characterized by reduced apoptosis and also by decreased proliferation. However, when Bcl-2 or BclXL forms a heterodimeric complex with BAD, cells can overcome the G0/G1 growth arrest and enter into S phase [17, 18] .
These findings were extended to T cells by showing that T-cells over-expressing BAD were more likely to remain in S-phase [19] .
In other recent reports, BAD in the phosphorylated form was found to promote assembly of active glucokinase complexes, an initial step of the glycolytic pathway [20, 21] . Although both increased proliferation and glycolysis are hallmarks of tumor growth, the experimental evidence that connects BAD expression with tumor growth has been lacking.
Could BAD play a dual role in prostate cancer cells? Several reports have shown that cells that
express BAD proliferate faster; however, mechanistic details on how BAD promotes proliferation diverge. One possibility is that BAD provides a counterbalance for increased levels of BclXL and Bcl-2 that are known to slow proliferation [22] . If this scenario is correct, any pro-apoptotic such an antagonist is constitutive, it would defeat the purpose of increased Bcl-2/BclXL expression by increasing apoptosis sensitivity. Since the proportion of BAD that could form heterodimers with anti-apoptotic counterparts depend on phosphorylation status, BAD may be uniquely suited for the role of modulator of BCl2/BClXL, availability of which is fine tuned by protein kinases. It is also possible that by increasing rate of glucose utilization, BAD expression provides competitive advantage to the cells in hypoxic tumors that switch from oxidative phosphorylation to glycolysis [23] .
The precise mechanism of how Bcl proteins regulate proliferation is obscure. It remains to be determined whether a single mechanism plays a dominant role or BAD-dependent stimulation of proliferation is mediated via several mechanisms simultaneously, and whether BAD localization to a specific organelle (e.g. mitochondria, ER, nuclear envelope) is important. Also, this positive effect on cell division may not be uniformly manifested in all cancer cells. Thus, BAD reportedly inhibits G1 to S transition in MCF7 breast cancer cells [24] . Until the effects of BAD on proliferation are dissected on a molecular level, we remain with the notion that effects of BAD expression on proliferation are cell type-dependent. 
